Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results From the Global Phase 2b Trial of Rademikibart in Patients With Moderate-to-Severe Asthma
Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results From the Global Phase 2b Trial of Rademikibart in Patients With Moderate-to-Severe Asthma
SAN DIEGO, CA and TAICANG, China, May 07, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the "Company"), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced data from its global Phase 2b trial of rademikibart in patients with moderate-to-severe asthma was accepted as a late-breaking abstract for poster presentation at the upcoming ATS 2024 International Meeting being held May 17-22, 2024 in San Diego, CA.
加利福尼亚州圣地亚哥和中国太仓，2024年5月7日（GLOBE NEWSWIRE）——Connect Biopharma Holdings Limited（纳斯达克股票代码：CNTB）（“Connect Biopharma” 或 “公司”）是一家全球临床阶段的生物制药公司，致力于通过开发源自T细胞研究的疗法来改善慢性炎症性疾病患者的生活，今天公布了其全球2b期试验的数据针对中度至重度哮喘患者的rademikibart被接受为即将到来的ATS 2024海报展示的最新摘要国际会议将于2024年5月17日至22日在加利福尼亚州圣地亚哥举行。
Poster Presentation Details:
海报 演示详情：
Title: Improved Lung Function and Asthma Control Observed with Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma (CBP-201-WW002)
标题：使用Rademikibart观察到中度至重度不受控制的哮喘（CBP-201-WW002）患者的肺功能和哮喘控制得到改善
Presenter: Edward Kerwin, M.D.
主持人：爱德华·克文，医学博士
Session: Poster Discussion D21: Terminator: Control of Airway Inflammation and Immune Response in Asthma
会议：海报讨论 D21：终结者：控制哮喘的气道炎症和免疫反应
Session Date and Time: Wednesday, May 22, 2024 at 8:15 AM – 10:15 AM PT
会议日期和时间：太平洋时间 2024 年 5 月 22 日星期三上午 8:15 — 上午 10:15
Location: San Diego Convention Center, Room 31A-C (Upper Level)
地点：圣地亚哥会议中心，31A-C室（上层）
Additionally, the poster presentation will be available as an ePoster on the ATS 2024 International Conference website, and will be available for viewing May 19 - 22, 2024.
此外，海报演示将作为电子海报在ATS 2024国际会议网站上发布，并将于2024年5月19日至22日可供观看。
About Connect Biopharma Holdings Limited
关于 Connect 生物制药控股有限公司
Connect Biopharma is a global, clinical-stage biopharmaceutical company applying its expertise in T cell biology and deep knowledge of the drug discovery industry to develop innovative therapies to treat chronic inflammatory diseases with the goal of improving the lives of millions of those affected around the world. The Company is building a rich pipeline of proprietary small molecules and antibodies, using functional T cell assays, to screen and discover potent product candidates against validated immune targets. The Company's lead product candidate, rademikibart (formerly known as CBP-201), is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. The Company's second product candidate, icanbelimod (formerly known as CBP-307), is a modulator of S1P1 T cell receptors and is in development for the treatment of ulcerative colitis (UC). For more information, please visit: https://www.connectbiopharm.com/
Connect Biopharma是一家全球性的临床阶段生物制药公司，运用其在T细胞生物学方面的专业知识和对药物发现行业的深入了解，开发治疗慢性炎症性疾病的创新疗法，目标是改善全球数百万受影响者的生活。该公司正在建立丰富的专有小分子和抗体产品线，使用功能性T细胞检测，对照经过验证的免疫靶标筛选和发现有效的候选产品。该公司的主要候选产品rademikibart（前身为 CBP-201）是一种抗体，旨在靶向正在开发的用于治疗特应性皮炎（AD）和哮喘的白介素-4受体α受体（IL-4Rα）。该公司的第二种候选产品icanbelimod（前身为 CBP-307）是S1P1 T细胞受体的调节剂，正在开发用于治疗溃疡性结肠炎（UC）。欲了解更多信息，请访问： https://www.connectbiopharm.com/
INVESTOR CONTACT:
投资者联系人：
Tim McCarthy
蒂姆·麦卡锡
LifeSci Advisors
生命科学顾问